Masthead
About Medicine Semaglutide.
An independent reading room for the semaglutide literature — what it is, what it isn't, and how it's built.
What this is
Medicine Semaglutide is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on semaglutide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site reads the literature the way a careful reader would: lead with what the studies actually measured, attribute every number to its source, and keep the honest open questions in plain view rather than papering over them. The leading lens here is the appetite mechanism — how semaglutide acts on the brain's hunger circuits — because that is the part that most clarifies everything else the drug does.
What the name means
The word "medicine" in the name is editorial framing, not a service claim. It marks the stance this publisher takes toward the literature: semaglutide is a real, FDA-approved medicine, and this digest treats it as such — measured, sourced, and free of the storefront language that surrounds it elsewhere. It does not mean this site dispenses, prescribes, or sells anything. There is no pharmacy here and no clinic behind the page.
That distinction matters because much of what is written about semaglutide online is either marketing or alarmism. This digest aims to be neither — a reading surface for the science, where the trials, the mechanism, and the cautions each get their due.
How it's made
Each page is built from a reviewed body of source material: the pivotal randomized trials (STEP, SUSTAIN, SELECT, FLOW), the mechanism studies in journals such as JCI Insight and Molecular Metabolism, dedicated safety reviews, and post-marketing pharmacovigilance analyses. Quantitative claims are tied to numbered citations, collected on the Semaglutide references page with DOIs and PubMed links.
We separate two kinds of information deliberately and visibly: what controlled trials established, and what the patient community reports. The latter is always labeled anecdotal and never presented as proof. Where the evidence is genuinely unsettled — the unconfirmed pancreatic and thyroid signals, the long-term durability question — we say so. The goal is a digest a curious non-scientist can trust to be honest about both the strength and the limits of the record.